文献速递肿瘤 PET/CT

68Ga-THP-PSMA PET-CT 对高危与生化复发前列腺癌管理的影响

The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-12-23

高危组24%管理改变,生化复发组34%管理改变,扫描阳性率随PSA升高而增加。

要点

  • 高危组24%管理改变,PSA<20 μg/L者改变更频繁(34.6% vs 12.5%)。
  • 生化复发组34%管理改变,扫描阳性率随PSA升高从0%增至91%。
  • PSAdt<6个月和Gleason评分>8与更高扫描阳性率相关。

核心结论

  • 68Ga-THP-PSMA PET-CT显著影响高危前列腺癌根治前和生化复发患者的管理。

主要发现

  • 高危组12/50(24%)管理改变,其中9例跨模式、3例模式内改变。
  • 生化复发组23/68(34%)管理改变,其中17例跨模式、6例模式内改变。
  • 高危组Gleason评分>8与更多淋巴结和骨转移检出相关。
  • 生化复发组PSAdt<6个月和Gleason评分>8与更高扫描阳性率相关。

关键数值与推荐

  • 高危组PSA<20 μg/L者管理改变9/26(34.6%),PSA>20 μg/L者3/24(12.5%)。
  • 生化复发组扫描阳性率:PSA<0.5 μg/L为0%,0.5-1.0 μg/L为35%,1.0-5.0 μg/L为69%,5.0-10.0 μg/L为91%。
  • 生化复发组PSAdt<6个月阳性率56% vs 45.7%,Gleason评分>8阳性率78.9% vs 51.2%。

临床怎么用

  • 对高危前列腺癌根治前和生化复发患者,可考虑68Ga-THP-PSMA PET-CT以指导管理决策。
  • 低PSA(<0.5 μg/L)生化复发患者扫描阳性率低,需结合PSAdt和Gleason评分综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the impact on clinical management of patients with high-risk (HR) prostate cancer at diagnosis and patients with biochemical recurrence (BCR) using a new kit form of 68Ga-prostate-specific membrane antigen (PSMA), namely tris(hydroxypyridinone) (THP)-PSMA, with positron emission tomography-computed tomography (PET-CT). METHODS: One hundred eighteen consecutive patients (50 HR, 68 BCR) had management plans documented at a multidisciplinary meeting before 68Ga-THP-PSMA PET-CT. Patients underwent PET-CT scans 60-min post-injection of 68Ga-THP-PSMA (mean 159 ± 21.2 MBq). Post-scan management plans, Gleason score, prostate-specific antigen (PSA) and PSA doubling time (PSAdt) were recorded. RESULTS: HR group: 12/50 (24%) patients had management changed (9 inter-modality, 3 intra-modality). Patients with PSA < 20 μg/L had more frequent management changes (9/26, 34.6%) compared with PSA > 20 μg/L (3/24, 12.5%). Gleason scores > 8 were associated with detection of more nodal (4/16, 25% vs 5/31, 16.1%) and bone (2/16, 12.5% vs 2/31, 6.5%) metastases. BCR group: Clinical management changed in 23/68 (34%) patients (17 inter-modality, 6 intra-modality). Forty out of 68 (59%) scans were positive. Positivity rate increased with PSA level (PSA < 0.5 μg/L, 0%; PSA 0.5-1.0 μg/L, 35%; PSA 1.0-5.0 μg/L, 69%; PSA 5.0-10.0 μg/L, 91%), PSAdt of < 6 months (56% vs 45.7%) and Gleason score > 8 (78.9% vs 51.2%). CONCLUSIONS: 68Ga-THP-PSMA PET-CT influences clinical management in significant numbers of patient with HR prostate cancer pre-radical treatment and is associated with PSA. Management change also occurs in patients with BCR and is associated with PSA and Gleason score, despite lower scan positivity rates at low PSA levels < 0.5 μg/L.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kulkarni M, Hughes S, Mallia A, et al. The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31872280. doi:10.1007/s00259-019-04643-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。